-Consult physician at once if watery and bloody stools (with or without stomach cramps and fever) develop. What Is the Risk of Catching the Coronavirus on a Plane? Children: Urinary tract Infection, soft tissue infection and skin infections: 10 mg/kg/dose IV every 8 hours. Non species related breakpoints are based on the following dosages: EUCAST breakpoints apply to meropenem 1000 mg x 3 daily administered intravenously over 30 minutes as the lowest dose. Four hundred forty-six patients (397 pediatric patients 3 months to less than 17 years of age) were enrolled in 4 separate clinical trials and randomized to treatment with meropenem (n=225) at a dose of 40 mg/kg every 8 hours or a comparator drug, i.e., cefotaxime (n=187) or ceftriaxone (n=34), at the approved dosing regimens. -Estimated GFR (eGFR) based on the Modification of Diet in Renal Disease equation. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Meropenem Updated September 2016 $48.50 for 500mg $63.50 for 1g Example A 30kg dog has a resistant urinary tract infection that is sensitive to meropenem. Infants <32 weeks GA and PNA <2 weeks: 20 mg/kg IV q12hr, Infants <32 weeks GA and PNA ≥2 weeks: 20 mg/kg IV q8hr, Infants ≥32 weeks GA and PNA <2 weeks: 20 mg/kg IV q8hr, Infants ≥32 weeks GA and PNA ≥2 weeks: 30 mg/kg IV q8hr, No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively; in rats administered intravenous meropenem in late pregnancy and during lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the MRHD based on body surface area comparison. To view formulary information first create a list of plans. Klebsiella pneumoniae has been frequently found to produce extended-spectrum β-lactamases (ESBLs).1 Infections caused by ESBL-producing pathogens are problematic because when co-resistance to other antimicrobial class is present, limited antibiotic options are available. Indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species, 500 mg IV q8hr; not to exceed 2 g IV q8hr, Indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species, 500 mg IV q8hr for ≤5 days in combination with fluoroquinolone, Indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae (penicillin susceptible isolates), Haemophilus influenzae, and Neisseria meningitidis, ≥3 months: 40 mg/kg IV q8hr; not to exceed 2 g IV q8hr, ≥3 months: 20 mg/kg IV q8hr; not to exceed 1 g q8hr, ≥3 months: 10 mg/kg IV q8hr; not to exceed 500 mg IV q8hr, Rash (2-3%; includes diaper-area moniliasis in pediatric patients), Oral moniliasis (≤2% in pediatric patients), Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme and acute generalized exanthematous pustulosis, Hypersensitivity to IV components, beta-lactams, or other drugs in this class, Hypersensitivity reactions have been reported, including fatalities; these reactions are more likely to occur in individuals with history of sensitivity to multiple allergens, Seizures have been reported, most commonly in patients with CNS disorders (eg, brain lesions, history of seizures) or with bacterial meningitis or compromised renal function, Seizures, headaches, or paresthesias may occur, potentially interfering with mental alertness or causing motor impairment, Clostridium difficile-associated diarrhea has been reported, To avoid development of drug resistance, drug should be used only in proven or strongly suspected bacterial infections or a prophylactic indication, Prolonged use may result in overgrowth of nonsusceptible organisms, Thrombocytopenia has been reported in patients with renal impairment, Co-administration of meropenem IV with valproic acid or divalproex sodium reduces serum concentrations of valproic acid potentially increasing risk of breakthrough seizures, Severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalized exanthematous pustulosis (AGEP) reported; if signs and symptoms suggestive of these reactions appear, therapy should be withdrawn immediately and an alternative treatment considered, There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women, Drug has been reported to be excreted in human milk; no information is available on effects of drug on breast-fed child or on milk production; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breast-fed child from therapy or from the underlying maternal condition. Contact the applicable plan Meropenem (Merrem) is an injectable carbapenem and beta-lactam antibiotic that interferes with bacterial cell wall synthesis in sensitive organisms Has activity versus a wide array of organisms, including multi-drug resistant Acinetobacter baumannii, Pseudomonas aeruginosa and … The easiest way to dilute meropenem is to do 2 vials at a time. Meropenem 1 g IV q8H should be used for all severe urinary infections if the organism is susceptible. For a history of other serious reactions (Type II, III, or IV e.g., hemolytic anemia, – thrombocytopenia, serum sickness, erythema multiforme, SJS/TEN, DRESS, etc), avoid the specifically implicated drug, … Meropenem is given intravenously by infusion or slow injection every 8 hours. IV compatibility: amoxicillin, doxycycline, ciprofloxacin, Macrobid, Augmentin, levofloxacin. 4 g IV every 8 hours Duration of therapy: Up to 14 days Use: For the treatment of patients with complicated urinary tract infections (including pyelonephritis) due to susceptible Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex. provider for the most current information. For pediatric patients from 3 months of age and older, the MERREM I.V. Ertapenem 1 g IV q24H can be used for uncomplicated UTI. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. We performed a prospective randomized open-label … •2g q8h –Cefepime 2g q 8h allowed only in “neutropenic fever” imipenem MIC of 4mg/L, the meropenem dose should be adjusted to 2 g q8hr. -Renal: Renal function in elderly patients; serum creatinine levels and eGFR in patients with changing renal function (at least daily) commonly, these are "non-preferred" brand drugs or specialty Double the dose in meningitis and severe infection. CONTRAINDICATIONS: complex. -Only compatible with 0.9% Sodium Chloride Injection, USP Reference(s) National Institutes of Health, U.S. National Library of Medicine, DailyMed Database. Meropenem/vaborbactam, sold under the trade name Vabomere among others, is a fixed dose combination drug for the treatment of complicated urinary tract infections.It contains the β-lactam antibiotic meropenem and the β-lactamase inhibitor vaborbactam.In August 2017, the U.S. Food and Drug Administration (FDA) approved it to treat complicated urinary tract infections and pyelonephritis. General: -The constituted solution must be diluted further (immediately) in a 0.9% Sodium Chloride Injection, USP infusion bag prior to IV infusion. Most Peritoneal dialysis: Data not available. meropenem, or cefepime (unless the reaction was to ceftazidime). This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.